Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria
Antibiotics · 05.05.2023 · 12 (5) · 858
DOI: 10.3390/antibiotics12050858 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 05.05.2023. Verfasst von Marta Palombo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology Unit, IRCCS Azienda Ospedaliera-University of Bologna, 40126 Bologna, Italy. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health (Ricerca Finalizzata, Giovani Ricercatori).
Abstract (Originalsprache)
Limited treatment options are among the main reasons why antimicrobial resistance has become a leading major public health problem. In particular, carbapenem-resistant Enterobacteriales (CRE), Pseudomonas aeruginosa and Acinetobacter baumannii have been included by the World Health Organization (WHO) among the pathogens for which new therapeutic agents are needed. The combination of antibiotics represents an effective strategy to treat multidrug-resistant (MDR) pathogen infections. In this context, the aim of this study is to evaluate the in vitro activity of cefiderocol (CFD) in combination with different antimicrobial molecules against a collection of well-characterized clinical strains, exhibiting different patterns of antimicrobial susceptibility. Clinical strains were genomically characterized using Illumina iSeq100 platform. Synergy analyses were performed by combining CFD with piperacillin-tazobactam (PIP-TAZ), fosfomycin (FOS), ampicillin-sulbactam (AMP-SULB), ceftazidime-avibactam (CAZ-AVI), meropenem-vaborbactam (MER-VAB) and imipenem-relebactam (IMI-REL). Our results demonstrated the synergistic effect of CFD in combination with FOS and CAZ-AVI against CRE and carbapenem-resistant Acinetobacter baumannii (CR-Ab) clinical strains owing CFD-resistant profile, while the CFD and AMP-SULB combination was effective against CR-Pa strain displaying AMP-SULB-resistant profile. Moreover, the combination of CAZ-AVI/SULB showed synergistic activity in CAZ-AVI-resistant CRE strain. In conclusion, although further analyses are needed to confirm these results, our work showed the efficacy of CFD when used for synergistic formulations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Microbiology Unit, IRCCS Azienda Ospedaliera-University of Bologna, 40126 Bologna, Italy.
- Department of Agricultural and Food Sciences, Alma Mater Studiorum-University of Bologna, 40126 Bologna, Italy.
ORCID-Profile: Federica Bovo, Stefano Amadesi, Paolo Gaibani
Förderung
- Italian Ministry of Health (Ricerca Finalizzata, Giovani Ricercatori)
Zitieren
APA
Palombo, M., Bovo, F., Amadesi, S., & Gaibani, P. (2023). Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria. Antibiotics, 12(5), 858. https://doi.org/10.3390/antibiotics12050858
Vancouver
Palombo M, Bovo F, Amadesi S, Gaibani P. Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria. Antibiotics. 2023;12(5):858. doi:10.3390/antibiotics12050858
BibTeX
@article{Palombo2023,
author = {Palombo, Marta and Bovo, Federica and Amadesi, Stefano and Gaibani, Paolo},
title = {Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria},
journal = {Antibiotics},
year = {2023},
volume = {12},
number = {5},
pages = {858},
doi = {10.3390/antibiotics12050858}
}
EUVIMED